Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 11—November 2011

CME ACTIVITY - Research

Global Distribution and Epidemiologic Associations of Escherichia coli Clonal Group A, 1998–2007

James R. JohnsonComments to Author , Megan E. Menard, Tsai-Ling Lauderdale, Chris Kosmidis, David Gordon, Peter Collignon, Joel N. Maslow, Arjana Tambić Andrašević, and Michael A. Kuskowski
Author affiliations: Veterans Affairs Medical Center, Minneapolis, Minnesota, USA (J.R. Johnson, M.E. Menard, M.A. Kuskowski); University of Minnesota, Minneapolis (J.R. Johnson, M.A. Kuskowski); National Health Research Institutes, Zhunan, Taiwan (T.-L. Lauderdale); University of Athens Medical School, Athens, Greece (C. Kosmidis); Australian National University, Canberra, Australian Capital Territory, Australia (D. Gordon, P. Collignon); Canberra Hospital, Canberra (P. Collignon); Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA (J.N. Maslow); University of Pennsylvania, Philadelphia (J.N. Maslow); University Hospital for Infectious Diseases, Zagreb, Croatia (A. Tambić Andrašević)

Main Article

Table 3

Prevalence of clonal group A, by region and TMP/SMZ phenotype, among 2,210 extraintestinal Escherichia coli isolates from 32 globally distributed centers, 1998–2007*

Region No. clonal group A isolates/total no. (%) p value†
Total TMP/SMZ susceptible TMP/SMZ resistant
Overall 144/2,210 (6.5) 30/1,083 (2.8) 114/1,127 (10.1) <0.001
Africa 3/92 (3.3) 0/21 (0) 3/71 (4.2)
Asia 18/476 (3.8) 8/225 (3.6) 10/251 (4.0)
Australia/New Zealand 14/172 (8.1) 3/88 (3.4) 11/84 (13.1) 0.025
Europe 30/398 (7.5) 4/198 (2.0) 26/200 (13.0) <0.001
North America 63/858 (7.3) 12/471 (2.5) 51/387 (13.2) <0.001
South/Central America 16/214 (7.5) 3/80 (3.8) 13/134 (9.7)
Africa/Asia combined 21/568 (3.7) 8/246 (3.3)‡ 13/322 (4.0)§
Not Africa/Asia 123/1,642 (7.5) 22/837 (2.6)‡ 101/805 (12.5)§ <0.001

*TMP/SMZ, trimethoprim/sulfamethoxazole.
†p values, by Fisher exact test, for TMP/SMZ-susceptible vs. -resistant isolates are shown where p<0.05; otherwise, p>0.10.
‡For Africa/Asia vs. other, p>0.10.
§For Africa/Asia vs. other, p<0.001.

*TMP/SMZ, trimethoprim/sulfamethoxazole.
†p values, by Fisher exact test, for TMP/SMZ-susceptible vs. -resistant isolates are shown where p<0.05; otherwise, p>0.10.
‡For Africa/Asia vs. other, p>0.10.
§For Africa/Asia vs. other, p<0.001.

*TMP/SMZ, trimethoprim/sulfamethoxazole.
†p values, by Fisher exact test, for TMP/SMZ-susceptible vs. -resistant isolates are shown where p<0.05; otherwise, p>0.10.
‡For Africa/Asia vs. other, p>0.10.
§For Africa/Asia vs. other, p<0.001.

Main Article

1Investigators who contributed data are listed at the end of this article.

TOP